Poor correlation between clinical disease activity and mucosal inflammation, and the role of psychological comorbidity, in inflammatory bowel disease

American Journal of Gastroenterology

Volumn 111, Issue 4, 2016, Pages 541-551

  Gracie, David J ^a,b   Williams, Christopher J M ^a   Sood, Ruchit ^a,b   Mumtaz, Saqib ^a   Bholah, M Hassan ^a   Hamlin, P John ^a   Ford, Alexander C ^a,b  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN; GLUCOCORTICOID; MESALAZINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; BIOLOGICAL MARKER;

ADULT; ANXIETY; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CORTICOSTEROID THERAPY; CROHN DISEASE; CROSS-SECTIONAL STUDY; DEPRESSION; DISEASE ACTIVITY; FECES ANALYSIS; FEMALE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MIDDLE AGED; MUCOSA INFLAMMATION; PATIENT HEALTH QUESTIONNAIRE 15; PREDICTIVE VALUE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; SECONDARY HEALTH CARE; SENSITIVITY AND SPECIFICITY; SOMATIZATION; ULCERATIVE COLITIS; PATIENT-REPORTED OUTCOME; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; SEVERITY OF ILLNESS INDEX;

BIOMARKERS; COMORBIDITY; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MENTAL DISORDERS; MIDDLE AGED; PATIENT REPORTED OUTCOME MEASURES; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX;

EID: 84964963327     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2016.59     Document Type: Article

References (47)

1. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn?s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007; 5: 1424-9
2. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the Inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46-54 e42. quiz e30
3. Vivinus-Nebot M, Frin-Mathy G, Bzioueche H, et al. Functional bowel symptoms in quiescent Inflammatory bowel diseases: role of epithelial barrier disruption and low-grade Inflammation. Gut 2014; 63: 744-52
4. van Hoboken EA, Th ijssen AY, Verhaaren R, et al. Symptoms in patients with ulcerative colitis in remission are associated with visceral hypersensitivity and mast cell activity. Scand J Gastroenterol 2011; 46: 981-7
5. Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in Inflammatory bowel disease: systematic review and meta-Analysis. Am J Gastroenterol 2012; 107: 1474-82
6. Tribbick D, Salzberg M, Ftanou M, et al. Prevalence of mental health disorders in Inflammatory bowel disease: an Australian outpatient cohort. Clin Exp Gastroenterol 2015; 8: 197-204
7. Walker JR, Ediger JP, Graff LA, et al. The Manitoba IBD cohort study: a population-based study of the prevalence of lifetime and 12-month anxiety and mood disorders. Am J Gastroenterol 2008; 103: 1989-97
8. Fuller-Thomson E, Lateef R, Sulman J. Robust association between Inflammatory bowel disease and generalized anxiety disorder: fi ndings from a nationally representative Canadian study. Inflamm Bowel Dis 2015; 21: 2341-8
9. Kappelman MD, Long MD, Martin C, et al. Evaluation of the patientreported outcomes measurement information system in a large cohort of patients with Inflammatory bowel diseases. Clin Gastroenterol Hepatol 2014; 12: 1315-23 e2
10. Falvey JD, Hoskin T, Meijer B, et al. Disease activity assessment in IBD: clinical indices and biomarkers fail to predict endoscopic remission. Inflamm Bowel Dis 2015; 21: 824-31
11. af Bjorkesten CG, Nieminen U, Turunen U, et al. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-Treated luminal Crohn?s disease. Scand J Gastroenterol 2012; 47: 528-37
12. Sipponen T, Savilahti E, Kolho KL, et al. Crohn?s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn?s disease activity index and endoscopic fi ndings. Inflamm Bowel Dis 2008; 14: 40-6
13. Jones J, Loftus EV Jr., Panaccione R, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn?s disease. Clin Gastroenterol Hepatol 2008; 6: 1218-24
14. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn?s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010; 105: 162-9
15. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn?s disease. N Engl J Med 2010; 362: 1383-95
16. Williet N, Sandborn WJ, Peyrin-Biroulet L. Patient-reported outcomes as primary end points in clinical trials of Inflammatory bowel disease. Clin Gastroenterol Hepatol 2014; 12: 1246-56 e6
17. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classifi cation of Inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19 ( Suppl A ): 5A-36A
18. Harvey RF, Bradshaw JM. A simple index of Crohn?s-disease activity. Lancet 1980; 1: 514
19. Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut 1998; 43: 29-32
20. Vermeire S, Schreiber S, Sandborn WJ, et al. Correlation between the Crohn?s disease activity and Harvey-Bradshaw indices in assessing Crohn?s disease severity. Clin Gastroenterol Hepatol 2010; 8: 357-63
21. Jowett SL, Seal CJ, Phillips E, et al. Defining relapse of ulcerative colitis using a symptom-based activity index. Scand J Gastroenterol 2003; 38: 164-71
22. Loitsch SM, Berger C, Hartmann F, et al. Comparison of two commercially available serologic kits for the detection of fecal calprotecin. Gatroenterology 2010; 138: S-528
23. Rogler G, Aldeguer X, Kruis W, et al. Concept for a rapid point-of-care calprotectin diagnostic test for diagnosis and disease activity monitoring in patients with Inflammatory bowel disease: expert clinical opinion. J Crohns Colitis 2013; 7: 670-7
24. Targownik LE, Sexton KA, Bernstein MT, et al. The relationship among perceived stress, symptoms, and Inflammation in persons with Inflammatory bowel disease. Am J Gastroenterol 2015; 110: 1001-12
25. D?Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in Inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 2218-24
26. Lin JF, Chen JM, Zuo JH, et al. Meta-Analysis: fecal calprotectin for assessment of Inflammatory bowel disease activity. Inflamm Bowel Dis 2014; 20: 1407-15
27. Longstreth GF, Th ompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91
28. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-70
29. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 1999; 282: 1737-44
30. Spitzer RL, Williams JB, Kroenke K, et al. Validity and utility of the PRIME-MD patient health questionnaire in assessment of 3000 obstetricgynecologic patients: the PRIME-MD Patient Health Questionnaire Obstetrics-Gynecology Study. Am J Obstet Gynecol 2000; 183: 759-69
31. Kroenke K, Arrington ME, Mangelsdorff AD. The prevalence of symptoms in medical outpatients and the adequacy of therapy. Arch Intern Med 1990; 150: 1685-9
32. Ford AC, Bercik P, Morgan DG, et al. Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology 2013; 145: 1262-70 e1
33. Cerrillo E, Beltran B, Pous S, et al. Fecal calprotectin in ileal Crohn?s disease: relationship with magnetic resonance enterography and a pathology score. Inflamm Bowel Dis 2015; 21: 1572-9
34. Stawczyk-Eder K, Eder P, Lykowska-Szuber L, et al. Is faecal calprotectin equally useful in all Crohn?s disease locations?. A prospective, comparative study. Arch Med Sci 2015; 11: 353-61
35. Kopylov U, Nemeth A, Koulaouzidis A, et al. Small bowel capsule endoscopy in the management of established Crohn?s disease: clinical impact, safety, and correlation with Inflammatory biomarkers. Inflamm Bowel Dis 2015; 21: 93-100
36. Gracie DJ, Kane JS, Mumtaz S, et al. Prevalence of, and predictors of, bile acid malabsorption in outpatients with chronic diarrhea. Neurogastroenterol Motil 2012; 24: 983-e538
37. Greco A, Caviglia GP, Brignolo P, et al. Glucose breath test and Crohn?s disease: diagnosis of small intestinal bacterial overgrowth and evaluation of therapeutic response. Scand J Gastroenterol 2015; 50: 1376-81
38. Goodhand JR, Wahed M, Mawdsley JE, et al. Mood disorders in Inflammatory bowel disease: relation to diagnosis, disease activity, perceived stress, and other factors. Inflamm Bowel Dis 2012; 18: 2301-9
39. Bryant RV, van Langenberg DR, Holtmann GJ, et al. Functional gastrointestinal disorders in Inflammatory bowel disease: impact on quality of life and psychological status. J Gastroenterol Hepatol 2011; 26: 916-23
40. Hyphantis TN, Tomenson B, Bai M, et al. Psychological distress, somatization, and defense mechanisms associated with quality of life in Inflammatory bowel disease patients. Dig Dis Sci 2010; 55: 724-32
41. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in Inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-To-Target. Am J Gastroenterol 2015; 110: 1324-38
42. Jairath V, Khanna R, Zou GY, et al. Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials. Aliment Pharmacol Ther 2015; 42: 1200-10
43. Khanna R, Zou G, D?Haens G, et al. A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn?s disease activity. Aliment Pharmacol Ther 2015; 41: 77-86
44. Jharap B, Sandborn WJ, Reinisch W, et al. Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis. Aliment Pharmacol Ther 2015; 42: 1082-92
45. McCombie A, Gearry R, Andrews J, et al. Does computerized cognitive behavioral therapy help people with Inflammatory bowel disease?. A randomized controlled trial. Inflamm Bowel Dis 2015
46. Mikocka-Walus A, Bampton P, Hetzel D, et al. Cognitive-behavioural therapy has no Effect on disease activity but improves quality of life in subgroups of patients with Inflammatory bowel disease: a pilot randomised controlled trial. BMC Gastroenterol 2015; 15: 54
47. Mikocka-Walus AA, Turnbull DA, Moulding NT, et al. Antidepressants and Inflammatory bowel disease: a systematic review. Clin Pract Epidemiol Ment Health 2006; 2: 24